



ISNI International Society
of Neuroimmunology

WE ARE NEUROIMMUNOLOGY

ISNI 2025

5-8 October

Chiba, Greater Tokyo-Japan

17th INTERNATIONAL CONGRESS

5th GLOBAL SCHOOL^{OF} NEUROIMMUNOLOGY

SCIENTIFIC PROGRAM

Disclaimer

This program reflects information received as of 28 September 2025.
Any subsequent updates or corrections will appear in the official
congress app, which will be continuously updated and available
for download onsite.



October 5

Convention Hall		International Conference Room	Room 201	Room 301	Room 303	Room 302
09:30	GSNI 2	Industry Forum ISNI White Paper Task Force 2				
11:10			Coffee Break			
11:30	GSNI 2	Sponsored Seminar CSL Behring 3				
13:10		Industry Forum Chugai Pharmaceutical 3	12:30			
14:10	Lunch Seminar (LT-1) Mitsubishi Tanabe 3	Lunch Seminar (LT-2) Novartis 3	Lunch Seminar (LT-3) Argenx 3	Lunch Seminar (LT-4) UCB 4		
15:50	GSNI 4	Sponsored Seminar Biogen 4	15:10			
16:10			Coffee Break			
16:40	Opening Ceremony 4	ISNI Keynote Lecture 4				
17:10	Giancarlo Comi Memorial Lecture 5					
17:40	Industry Forum: The Future of Neuroimmunology Round Table 5					
19:30	Welcome Reception 5					

October 6

	Convention Hall	International Conference Room	Room 201	Room 301	Room 303	Room 302	Room 101B - 105
08:15	Morning Lecture 1 ₅	Introductory Lecture on ALS ₅					
09:00	Plenary Lecture 1 ₅						
09:30	Microbiome & Neuroimmunology ₆	Immunology of MS (1) ₆	Stress, Depression & Neuroimmunology ₆	Myasthenia Gravis & Pathogenesis ₇			
11:10							
			Coffee Break				
11:30	ISNI Keynote Lecture ₇						
12:00	Immunology of MS (2) ₇	Regulatory Gene & Environmental Factors in MS (1) ₈	Memory, Emotion & Neuroimmune Interactions ₈	NMO & MOGAD ₈			
13:15							
14:15	Lunch Seminar (LT-5) Mitsubishi Tanabe ₉	Lunch Seminar (LT-6) Novartis ₉	Lunch Seminar (LT-7) Merck ₉	Lunch Seminar (LT-12) Argenx ₉	Meet the Experts 1 ₉	Meet the Experts 2 ₉	
14:45	Plenary Lecture 2 ₉						
		Mechanisms of Degeneration & Progression ₁₀	Human Immunology ₁₀	NMOSD ₁₁			
15:45							
		Coffee Break					
16:05	Microglia ₁₂	Regulatory Gene & Environmental Factors in MS (2) ₁₂	BBB & T cell Trafficking ₁₂	Investigator-Initiated Clinical Trials in Neuroimmunology ₁₂			
17:20							
17:50	Plenary Lecture 3 ₁₃						
19:15							Poster Session 1 ₁₃
19:45							
			Social Dinner				

ISNI 2025 Lunch Seminar


Advances in MG: IMMUNE pathology and EMERGING therapies

Room 201

Makuhari Messe, Chiba, Japan

Monday, 6 October 2025

13:15–14:00



Nicholas Sanderson

University of Basel
Switzerland



Heinz Wiendl

University Hospital Freiburg
Germany

**To learn more, visit our booth
in the exhibition hall**


MG, myasthenia gravis.

GL-NONNI-02436 | September 2025

This material has been developed by Merck's headquarters in Germany, and Merck BioPharma Co., Ltd., the Japanese branch, is not involved.

© 2025 Merck KGaA, Darmstadt, Germany, and/or its affiliates.
All rights reserved.

MERCK



Multiple Sclerosis Treatment/Human anti-CD20 monoclonal antibody

Kesimpta[®] for s.c. injection
20mg pen

Biological product Powerful Drug Prescription Drug*

*Caution-Use Only Pursuant to the
Prescription of a Physician, etc

Generic Name: Ofatumumab (Genetical Recombination) Listed for NHI Drug Price List

For efficacy, dosage and administration, warnings, contraindications,
and other precautions, please refer to the electronic package insert.

Manufacturing and Marketing (Import)
[Medical Inquiry & Literature Request]

Novartis Pharma K.K.
1-23-1, Toranomon Minato-ku Tokyo 105-6333 JAPAN

NOVARTIS DIRECT

TEL: 0120-003-293

Hours: Monday-Friday, 9:00-17:30 (excluding weekends and holidays)

Inquiries regarding
promotional activities

TEL: 0120-907-026

October 7

	Convention Hall	International Conference Room	Room 201	Room 301	Room 303	Room 302	Room 101B - 105
08:15	Morning Lecture 2 ¹³	Introductory Lecture on MG ¹³					
09:00	Plenary Lecture 4 ¹³						
09:30	Potential New Therapy ¹⁴	Glial Cells: Biology & Disease ¹⁴	Neuropathology of MS/NMO: Updated ¹⁴	Gut-brain Axis & Microbiome ¹⁵			
11:10							
			Coffee Break				
11:30	Round Table 1 ISNI White Paper ¹⁵						
12:30							
13:30	Lunch Seminar (LT-8) Chugai Pharmaceuticals ¹⁵	Lunch Seminar (LT-9) Novartis ¹⁵	Lunch Seminar (LT-11) Biogen ¹⁵		Meet the Experts 3 ¹⁵	Meet the Experts 4 ¹⁵	
14:50	Alzheimer's Disease: New Perspective ¹⁶	Neuro-immune Crosstalk ¹⁶	Destructive & Protective Immunity in Neurodegenerative Conditions ¹⁶	MG/CIDP ¹⁶			
15:20	ISNI Keynote Lecture ¹⁷						
			Coffee Break				
15:40	ISNI Mid Career Award ¹⁷						
16:40		Tech Symposium ¹⁷	Sponsored Seminar Alexion ¹⁸				
18:20			17:40				
19:40							Poster Session 2 ¹²

October 8

	Convention Hall	International Conference Room	Room 201	Room 301	Room 303	Room 302
08:15						
09:00	Morning Lecture 3 18	Morning Lecture for Clinical Topic 3 18				
09:30	ISNI Keynote Lecture 18					
09:50			Coffee Break			
11:30	Infectious Agents, Molecular Mimicry & Neuroimmunological Disorders 19	ISNI Young Session Sponsored by Elsevier/JNI 19	Human Immunology & Neuroimmunology 19	Hot Topics in Neuroimmunology Research 20		
12:00	Henry McFarland Memorial Lecture 20					
12:30	Closing Ceremony & Awards 20					

Transforming Lives. Every Day.

アレクシオン・アストラゼネカ・レアディジーズは、希少疾患ならびに深刻な病状の患者さんと
そのご家族の人生を一変させるような治療薬を発見、開発し、お届けすることを使命としています。

<https://www.alexionpharma.jp/>



We don't only fight disease.
We also take on drug discovery paradigms.
Our unprecedented medicines are
a step ahead of illness.
And when the world says there's no cure,
we don't give up until we find one.

INNOVATION BEYOND IMAGINATION



CHUGAI

CHUGAI PHARMACEUTICAL

 A member of the Roche group

DAY 1 | October 5

09:30 – 11:10

Convention Hall

GSNI

Welcome remarks & Co-Chairs

Wee Yong (*Canada*) & Takashi Yamamura (*Japan*)

Immune routes to the CNS

Aleksandra Deczkowska (*University Paris, France (ESNI)*)

CNS mononuclear phagocytes in health and disease

Sarah Mundt (*University of Zurich, Switzerland (ESNI)*)

Neuroimmunology of B cells: autoantibodies, cytokines, and beyond

Rui Li (*Fujian Medical University, China (APSN)*)

International Conference Room - Novartis Hall

Industry Forum | White Paper Task Force

09:30-10:00 **Use of Neuroimmunology Animal Models – Recommendations from the International Society for Neuroimmunology White Paper Task Force**

Moderator: Jen Gommerman (*University of Toronto – Toronto, ON, Canada*)

Katerina Akassoglou (*University of California San Francisco – San Francisco, CA, USA*) - online

Francisco Quintana (*Brigham and Women's Hospital, Harvard Medical School – Boston, MA, USA*)

Veronique Miron (*Unity Health Toronto & The University of Toronto – Toronto, ON, Canada*)

10:00-10:30 **A strategic roadmap for Human Clinical Translation in Neuroimmunology - Recommendations from the International Society for Neuroimmunology White Paper Task Force**

Moderator: Fabienne Brilot (*The University of Sydney – Sydney, Australia*)

Stefano Pluchino (*University of Cambridge – Cambridge, UK*) - online

Heinz Wiendl (*University of Freiburg – Freiburg, Germany*)

Amit Bar-Or (*University of Pennsylvania and Children's Hospital of Philadelphia (CHOP) – Philadelphia, PA, USA*)

10:30-11:10 **MS act: Future of clinical trials**

Moderator: Roberto Furlan (*San Raffaele Hospital - Milan, Italy*)

Xavier Montalban (*Vall d'Hebron University Hospital – Barcelona, Spain*)

Heinz Wiendl (*University of Freiburg – Freiburg, Germany*)

Frank Dahlke (*Basel, Switzerland*) - online

Maria Pia Sormani (*University of Genoa – Genoa, Italy*) - online

11:10 – 11:30 COFFEE BREAK

11:30 – 13:10

Convention Hall

GSNI

Chairs: Laura Piccio (*Australia*) & Olga Rojas (*Canada*)

T cell immunology with examples from Guillain-Barré syndrome and narcolepsy

Daniela Latorre (*San Raffaele Hospital, Milano, Italy (ESNI)*)

Neuroimmunology of neurodegenerative diseases

John Lukens (*University of Virginia, USA (ASNI)*)

Neuroinfections

Rachael Dangarembizi (*University of Cape Town, South Africa (AfSNI)*)

11:30 – 12:30

International Conference Room - Novartis Hall

Sponsored Seminar | CSL Behring

Chair: Satoshi Kuwabara (*Professor, Department of Neurology, Graduate School of Medicine, Chiba University – Chiba, Japan*)

Pathophysiology of CIDP: Insights into therapeutic strategy

Haruki Koike (*Professor, Department of Neurology, Saga University – Saga, Japan*)

Advances in CIDP Treatment: Current approaches based on the latest evidence

Todd Levine (*Director, HonorHealth Neurology - Bob Bové Neuroscience Institute. Assistant Professor Arizona State University – Tempe, AZ, USA*)

12:30 – 13:10

International Conference Room - Novartis Hall

Industry Forum | Chugai Pharmaceuticals

Taichi Kuramochi (*Chugai Pharmaceuticals*)

13:10 – 14:10

Convention Hall

Lunch Seminar (LT-1) | Mitsubishi Tanabe

Chair: Izumi Kawachi (*Medical Education Center Niigata University School of Medicine Dept. of Neurology Brain Research Institute Niigata University – Niigata, Japan*)

Clinical trial insights into the pathogenesis of neuromyelitis optica spectrum disorder

Michael Levy (*Massachusetts General Hospital – Boston, MA, USA*)

International Conference Room - Novartis Hall

Lunch Seminar (LT-2) | Novartis

Chair: Ichiro Nakashima (*Division of Neurology, Tohoku Medical and Pharmaceutical University Professor – Sendai, Japan*)

Kesimpta - latest data from ECTRIMS 2025

Bernd Kieseier (*Global Program Head, Drug Development, Novartis AG, Switzerland, Professor of Neurology at the Heinrich Heine University - Düsseldorf, Germany*)

Room 201 - Merck Hall

Lunch Seminar (LT-3) | Argenx

Chair: Sonoko Misawa (*Chairman and Professor, Department of Neurology and Neurological Science, Institute of Science Tokyo – Tokyo, Japan*)

Epidemiology and current status of CIDP

Tomoki Suichi (*Assistant Professor, Department of Neurology, Chiba University Graduate School of Medicine – Chiba, Japan*)

CIDP Treatment Update: Changing Treatment Strategies with VYVDURA

Yuki Fukami (*Designated Assistant Professor, Department of Neurology, Nagoya University Graduate School of Medicine – Nagoya, Japan*)

Room 301 - Mitsubishi Tanabe Hall

Lunch Seminar (LT-4) | UCB - Clinical Significance of MOG-IgG Assay in MOGAD Diagnosis and Latest Understanding of Pathophysiology

Chair: Kazuo Fujihara (*Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience – Fukushima, Japan*)

Clinical Significance of MOG-IgG Assay in MOGAD Diagnosis and Latest Understanding of Pathophysiology

Fabienne Brilot (*The University of Sydney – Sydney, Australia*)

Pathology of MOGAD

Yoshiki Takai (*Department of Neurology, Tohoku University Graduate School of Medicine, Department of Pathology, Tohoku University Hospital – Sendai, Japan*)

14:10 – 15:50

Convention Hall

GSNI

Chairs: Bieke Broux (*Belgium*) & Qiang Liu (*China*)

Neuroimmunology of the extracellular matrix

Samira Ghorbani (*University of Toronto, Canada (ASNI)*)

Neuroimmunology of stress

Tomoyuki Furuyashiki (*Institute of Science Tokyo, Japan (APSNII)*)

Neuroimmunology of pain

Issac Chiu (*Harvard University, USA (ASNI)*)

14:10 – 15:10

International Conference Room - Novartis Hall

Sponsored Seminar | Biogen

Chair: Takashi Yamamura (*National Center of Neurology and Psychiatry – Tokyo, Japan*)

A Lifetime Research in Multiple Sclerosis

Howard L. Weiner (*Brigham and Women's Hospital, Harvard Medical School – Boston, MA, USA*)

15:50 – 16:10 COFFEE BREAK

16:10 – 16:40

Convention Hall

Opening Ceremony & Presidential Handover

16:40 – 17:10

Convention Hall

ISNI Keynote Lecture | the Newsom-Davis Lecture

Chair: Alexandre Prat (*Canada*)

16:40-17:10 **Therapeutic strategies at the interface between immune and nervous system**
Frauke Zipp (*Johannes Gutenberg University Mainz – Mainz, Germany*)

17:10 – 17:40

Convention Hall

Giancarlo Comi Memorial Lecture

Chair: Roberto Furlan (*Italy*)

17:10-17:40 **Impact of early diagnosis on long-term prognosis of MS**
Xavier Montalban (*Vall d'Hebron University Hospital – Barcelona, Spain*)

17:40 – 19:30

Convention Hall

Industry forum: the future of clinical neuroimmunology – Round Table

Topics:

- 1) Future of MS R&D
- 2) Will neuroimmunology be relevant to understand and treat neurodegeneration
- 3) Peripheral neuroimmunology - MG, CIDP, Myositis
- 4) why ME/CFS, Long covid are not neuroimmunological diseases
- 5) how can academia help to develop therapeutic strategies

Merck – Dominic Jack & Hashem Salloukh

Novartis - Bernd Kieseier

Roche Global – Bjoern Tackenberg

19:30 Welcome Reception at Makuhari Messe

DAY 2 | October 6

08:15 – 09:00

Convention Hall

Morning Lecture 1

Chair: Roland Liblau (*France*)

08:15-09:00 **TBD**
Francisco Quintana (*Brigham and Women's Hospital, Harvard Medical School – Boston, MA, USA*)

International Conference Room - Novartis Hall

Morning Lecture for Clinical Topic 1 | Introductory Lecture on ALS

Chair: Susumu Kusunoki (*Japan*)

08:15-09:00 **ALS pathophysiology - from the standpoint of innate immunity and beneficial peripheral neuritis**
Ryo Yamasaki (*Kyushu University – Fukuoka, Japan*)

09:00 – 09:30

Convention Hall

Plenary Lecture 1

Chair: Takeshi Tabira (*Japan*)

09:00-09:30 **Treatment of autoimmune disease by converting disease-mediating T cells into Tregs**
Shimon Sakaguchi (*Osaka University – Osaka, Japan*)

09:30 – 11:10

Convention Hall

Symposium 1 | Microbiome & Neuroimmunology

Chairs: Sachiko Miyake (*Japan*) & Sergio Baranzini (*USA*)

- 09:30-09:50 **Dietary Modulation of Gut Microbiota and Immune-Metabolic Profiles in Multiple Sclerosis**
Laura Piccio (*University of Sydney – Sydney, Australia*)
- 09:50-10:10 **The gut-brain axis in autoimmune demyelination**
Sergio Baranzini (*University of California San Francisco – San Francisco, CA, USA*)
- 10:10-10:30 **Gut-Brain Connection in Multiple Sclerosis: From Microbial Signatures to Mechanisms and Translational Opportunities**
Ashutosh Mangalam (*University of Iowa – Iowa City, IA, USA*)
- 10:30-10:50 **Unmasking Microbial Culprits in MS via Strain-Level Profiling**
Daiki Takewaki (*National Center of Neurology and Psychiatry – Kodaira, Japan*)
- 10:50-11:10 **O-358 | Gut microbiota composition at the onset of Multiple Sclerosis can reveal rapid disease progression**
Alessandro Maglione (*University of Torino - Orbassano, Italy*)

International Conference Room - Novartis Hall

Symposium 2 | Immunology of MS (1)

Chairs: Tanuja Chitnis (*USA*) & Heinz Wiendl (*Germany*)

- 09:30-09:50 **Towards a biology driven characterization of MS**
Heinz Wiendl (*University of Freiburg – Freiburg, Germany*)
- 09:50-10:10 **Single-cell genomics and hiPSC-modelling of chronic CNS inflammation in multiple sclerosis**
Martina Absinta (*Humanitas University – Milan, Italy*)
- 10:10-10:30 **Decoding neuro-immune interactions in multiple sclerosis**
Manuel A. Friese (*University Medical Center Hamburg-Eppendorf – Hamburg, Germany*)
- 10:30-10:50 **Gene Regulatory Circuit of Treg Dysfunction in Multiple Sclerosis**
Tomokazu Sumida (*Yale School of Medicine – New Haven, CT, USA*)
- 10:50-11:10 **Biomarkers and mechanisms of MS relapse – a role for EBV**
Tanuja Chitnis (*Mass General Brigham, Harvard Medical School – Boston, USA*)

Room 201 - Merck Hall

Symposium 3 | Stress, Depression & Neuroimmunology

Chairs: Anna Victoria Molofsky (*USA*) & Scott Russo (*USA*)

- 09:30-09:50 **Brain-body circuits in stress and depression**
Scott Russo (*Icahn School of Medicine at Mount Sinai – New York, NY, USA*)
- 09:50-10:10 **Neuro-Immune-Metabolic Crosstalk Underlying Stress-Related Brain Pathology**
Tomoyuki Furuyashiki (*Kobe University – Kobe, Japan*)
- 10:10-10:30 **Extracellular matrix remodeling in brain development and learning**
Anna Victoria Molofsky (*University of California, San Francisco – San Francisco, CA, USA*)
- 10:30-10:50 **Do Environmental Stressors Drive Psychiatric Disorders via Immune Mechanisms?**
Atsushi Kamiya (*Johns Hopkins University School of Medicine – Baltimore, MD, USA*)
- 10:50-11:10 **O147 | Chronic Interleukin-1-induced DNA double-strand break response, a new player in inflammation-driven cognitive impairment from chronic to neurodegenerative disorders**
Elsa Suberbielle (*University of Toulouse - Toulouse, France*)

Room 301 - Mitsubishi Tanabe Hall

Symposium 4 | Myasthenia Gravis & Pathogenesis

Chairs: Maartje Huijber (*the Netherlands*) & Kenichi Kaida (*Japan*)

- 09:30-09:50 **Determinants of complement activation by patient-derived anti-AChR antibodies**
Nicholas Sr. R. Sanderson (*University Hospital Basel and University of Basel – Basel, Switzerland*)
- 09:50-10:10 **C5a-driven modulation of adaptip immunity and Thh cell dynamica in myasthenia gravis**
Takayuki Kondo (*Kansai Medical University Medical Center – Moriguchi, Japan*)
- 10:10-10:30 **Pathogenic mechanisms in MuSK myasthenia gravis and other IgG4 autoimmune diseases**
Maartje Huijber (*LUMC in Leiden – Leiden, the Netherlands*)
- 10:30-10:50 **O139 | Exploring cross-reactive T cell immunity in inflammatory peripheral neuropathies**
Christophe M. Capelle (*Institute of Microbiology, ETH - Zurich, Switzerland*)
- 10:50-11:10 **O311 | Identification of a Novel Metabolically Active B Cell Cluster in Refractory Myasthenia Gravis: Insights into Plasma Cell Precursors and Therapy Resistance Biomarkers**
Jacopo Morroni (*Fondazione Policlinico Universitario “A. Gemelli” IRCCS - Rome, Italy*)

11:10 – 11:30 COFFEE BREAK

11:30 – 12:00

Convention Hall

ISNI Keynote Lecture | The Rita Levi-Montalcini Neurobiology Lecture

Chair: Martina Absinta (*Italy*)

- 11:30-12:00 **The maestro of neuroinflammation and neurobiology: the extracellular matrix**
V. Wee Yong (*University of Calgary – Calgary, AB, Canada*)

12:00 – 13:15

Convention Hall

Symposium 5 | Immunology of MS (2)

Chairs: Frauke Zipp (*Germany*) & Masaaki Niino (*Japan*)

- 12:00-12:20 **Immune-CNS interactions in Relapsing and Progressive MS biology**
Amit Bar-Or (*University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) – Philadelphia, PA, USA*)
- 12:20-12:40 **Tissue protective glial interactions in autoimmune CNS inflammation**
Veit Rothhammer (*University Hospital Erlangen, Friedrich-Alexander University – Erlangen-Nürnberg, Germany*)
- 12:40-13:00 **Toward biology-based precision medicine of MS**
Takashi Yamamura (*National Institute of Neuroscience, NCNP – Tokyo, Japan*)
- 13:00-13:15 **O144 | MS-associated HLA class I alleles demarcate EBV-specific CD8+ T cells with an exhausted and CNS residency phenotype**
Marvin van Luijn (*Erasmus MC, University Medical Center Rotterdam – Rotterdam, the Netherlands*)

International Conference Room - Novartis Hall

Symposium 6 | Regulatory Gene & Environmental Factors in MS (1)

Chair: Helmut Butzkueven (*Australia*) & Jin Nakahara (*Japan*)

- 12:00-12:20 **Decoding environmental triggers in MS**
Anne-Katrin Pröbstel (University Hospital and University Bonn – Bonn, Germany)
- 12:20-12:40 **Genetic Susceptibility and Environmental Influences in MS: An Epidemiological Perspective**
Noriko Isobe (Kyushu University – Fukuoka City, Japan)
- 12:40-13:00 **Epigenome as a mediator of risk factors in Multiple Sclerosis**
Maja Jagodic (Karolinska Institutet – Stockholm, Sweden)
- 13:00-13:15 **O352 Forever young – the epigenetic clock of OPCs in multiple sclerosis**
Assia Tiane (*Maastricht University - Maastricht, The Netherlands/Hasselt University – Hasselt, Belgium*)

Room 201 - Merck Hall

Symposium 7 | Memory, Emotion & Neuroimmune Interactions

Chairs: Aleksandra Deczkowska (*France*) & Hideyuki Takeuchi (*Japan*)

- 12:00-12:20 **Immune-brain communication at the choroid plexus**
Aleksandra Deczkowska (*Université Paris Cité – Paris, France*)
- 12:20-12:40 **Mechanisms of Anxiety-like Behaviors using a Novel Mouse Model of Multiple Sclerosis**
Makoto Inoue (*The University of Illinois at Urbana-Champaign – Champaign, IL, USA*)
- 12:40-13:00 **Rewiring neuroimmune circuits in psychiatry: From psychedelics to immunomodulation**
Michael Wheeler (*Harvard Medical School – Boston, MA, USA*)
- 13:00-13:15 **O61 | Adverse childhood experiences and their impact on disease onset, mental health, and lifestyle factors in patients with multiple sclerosis and neuromyelitis optica spectrum disorder**
Yuta Inagawa (*Tokyo Medical University – Tokyo, Japan*)

Room 301 - Mitsubishi Tanabe Hall

Symposium 8 | NMO & MOGAD

Chairs: Fabienne Brilot (*Australia*) & Norio Chihara (*Japan*)

- 12:00-12:20 **NMOSD and MOGAD: next challenges**
Fabienne Brilot (*The University of Sydney – Sydney, Australia*)
- 12:20-12:40 **Bone marrow immunity in neuromyelitis optica**
Qiang Liu (*Tianjin Medical University General Hospital – Tianjin, China*)
- 12:40-13:00 **A fresh look at B cells in CNS autoimmunity**
Thomas Korn (*Technical University of Munich School of Medicine and Health – Munich, Germany*)
- 13:00-13:15 **O423 | Endothelial cell-secreted SPARC suppresses astrocytic CD59 expression and promotes autoimmune astrocytopathy**
Yaping Yan (*Shaanxi Normal University - Xi'an, China*)

13:15 – 14:15

Convention Hall

Lunch Seminar (LT-5) | Mitsubishi Tanabe

Chair: Ichiro Nakashima (*Tohoku Medical and Pharmaceutical University – Sendai, Japan*)

Therapeutic Strategies for NMOSD with Focusing on Long-Term Disease Management

Shuhei Nishiyama (*Department of Neurology, Tohoku University Hospital – Sendai, Japan*)

International Conference Room - Novartis Hall

Lunch Seminar (LT-6) | Novartis

Chair: Noriko Isobe (*Department of Neurology, Graduate School of Medical Sciences, Kyushu University – Fukuoka, Japan*)

Family Planning and MS Could Also Be an Option

Kerstin Hellwig (*St. Josef Hospital / Ruhr University - Bochum, Germany*)

Room 201 Merck Hall

Lunch Seminar (LT-7) | Merck - Advances in MG: Immune pathology and emerging therapies

Chairs: Heinz Wiendl (*University of Freiburg – Freiburg, Germany*)

Pathways and progress: How novel MoAs are reshaping MG treatment

Nicholas Sanderson (*University Hospital Basel and University of Basel – Basel, Switzerland*)

The next chapter in MG: Exploring B and T cell dynamics in the context of emerging therapies

Heinz Wiendl (*University of Freiburg – Freiburg, Germany*)

Room 301 - Mitsubishi Tanabe Hall

Lunch Seminar (LT-12) | Argenx - Update on gMG treatment strategies

Chair: Shunya Nakane, MD, PhD (*Department of Neurology, Faculty of Medicine, Academic Research Division, University of Toyama - Toyama, Japan*)

Optimization for Symptom Stabilization and Oral Corticosteroid Reduction with Efgartigimod: Insights from Clinical Practice in gMG

Satoru Oji (*Department of Neurology, Saitama Medical University General Medical Center - Saitama, Japan*)

Key points of Efgartigimod Treatment Strategy based on the Japanese MG Guidelines 2025 Supplement

Hiroyuki Murai (*Department of Neurology, International University of Health and Welfare - Tochigi, Japan*)

Room 302

Meet the Experts 1

Room 303

Meet the Experts 2

14:15 – 14:45

Convention Hall

Plenary Lecture 2

Chair: V. Wee Yong (*Canada*)

14:15-14:45

TBD

Marco Colonna (*University of Washington in St. Louis – St. Louis, MO, USA*)

14:45 – 15:45

International Conference Room - Novartis Hall

Pecha Kucha 1 | Mechanisms of Degeneration & Progression

Chair: Alexander Flügel (*Germany*) & Shinji Oki (*Japan*)

- 14:45-14:52 **PK111 | Deciphering The Role of CD4 and CD8 T cells in the Pathophysiology of Alzheimer's Disease and Other Tauopathies**
Karen Matta (*Sorbonne University, INSERM - Paris, France*)
- 14:52-14:59 **PK116 | Benign Autoimmunity via Inverse Vaccination: Stabilized Self-Peptides Generate Armored Tissue-Specific Effector Regulatory T Cells with Dual Suppression and Repair Functions**
Youwei Lin (*National Institute of Neuroscience, National Center of Neurology and Psychiatry - Tokyo, Japan*)
- 14:59-15:06 **PK119 | A centrally acting connexin blocker attenuates multiple system atrophy-cerebellar type by facilitating α -synuclein oligomer sharing among glial cells and suppressing glial inflammation**
Masaya Harada (*Kyushu University - Fukuoka, Japan/Kurume University School of Medicine - Kurume, Japan*)
- 15:06-15:13 **PK463 | Engineered brain-homing CAR T cells as a modular platform for drug delivery to the brain**
William Xie (*Gladstone Institute of Neurological Disease - San Francisco, CA, USA*)
- 15:13-15:20 **PK427 | Chronic stress-driven B cell aging in the meninges: a sex-dimorphic pathway to immune dysregulation**
Alara S Tuncer (*University of Toronto/Sunnybrook Health Sciences Centre - Toronto, ON, Canada*)
- 15:20-15:27 **PK350 | CD103-CD8⁺ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling**
Gabriela Constantin (*University of Verona - Verona, Italy*)
- 15:27-15:34 **PK448 | TSPO probe preferentially labels metabolism disturbance microglia in demyelination: implications for in-vivo monitoring microglia-targeting therapies in MS**
Huanhuan Song (*Fujian Medical University - Fuzhou, China*)
- 15:34-15:41 **PK21 | Immunoregulatory properties of MIF in the context of autoimmune CNS inflammation**
Anne Peter (*University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg - Erlangen, Germany*)

Room 201 - Merck Hall

Pecha Kucha 2 | Human Immunology

Chairs: Claudia Cantoni (*USA*) & Wakiro Sato (*Japan*)

- 14:45-14:52 **PK99 | Increased aryl hydrocarbon receptor agonistic activity correlates with Tim-1-positive B cells in multiple sclerosis**
Daniel Farrenkopf (*University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg - Erlangen, Germany*)
- 14:52-14:59 **PK103 | Mast cell-sensory neuron interactions drive neuroplasticity in a human in vitro asthma model**
Carli Koster (*University of Groningen - Groningen, The Netherlands*)
- 14:59-15:06 **PK115 | Uncovering the cellular landscape and interaction of leptomeningeal inflammation and cortical microglia in progressive MS**
Carla Rodriguez-Mogeda (*UMC location Vrije Universiteit Amsterdam - Amsterdam, The Netherlands*)

- 15:06-15:13 **PK118 | BTK inhibition influences B cell and monocyte phenotype and function in relapsing and progressive multiple sclerosis**
Rochelle Benoit (*Memorial University of Newfoundland - St. John's, NL, Canada*)
- 15:13-15:20 **PK287 | Selective cortical neuron vulnerability as a response to focal inflammatory demyelination**
Thomas Thäwel (*Division of Neuroimmunology - Mannheim, Germany*)
- 15:20-15:27 **PK292 | GZMH+GZNK+ DOUBLE POSITIVE CD8 T CELLS: EBV SPECIFIC T CELL EXPANSION IN CEREBROSPINAL FLUID OF MULTIPLE SCLEROSIS PATIENTS**
Shinji Ashida (*Kyoto Prefectural University of Medicine – Kyoto, Japan*)
- 15:27-15:34 **PK128 | Changes in mRNA expression in temporal lobe of patients with drug resistant epilepsy: a focus on neuroinflammation**
Tracie Tan (*Monash University, Melbourne, Alfred Hospital - Melbourne, Australia*)
- 15:34-15:41 **Dynamics of tissue-resident memory T cells in mixed-active/inactive lesions of multiple sclerosis in situ**
Fumihiko Yanagimura (*NHO Niigata National Hospital - Niigata, Japan*)

Room 301 - Mitsubishi Tanabe Hall

Pecha Kucha 3 | NMOSD & Autoimmune Encephalitis

Chairs: Noriko Isobe (*Japan*) & Shuhei Nishiyama (*Japan*)

- 14:45-14:52 **PK-6 | mRNA profiling of an AQP4-expressing human cell model identifies NF-κB and IL-6 pathway activation in neuromyelitis optica spectrum disorder**
Sarah Brandl (*Medical University of Innsbruck - Innsbruck, Austria*)
- 14:52-14:59 **PK-37 | a series of CD21^{lo} B cell subsets and B-helper T cell subsets are recruited to the cerebrospinal fluid in the acute phase of neuromyelitis optica.**
Ryusei Nishigori (*Kyoto University Graduate School of Medicine - Kyoto, Japan*)
- 14:59-15:06 **PK-53 | Retinoic acid – associated protection of the area postrema in neuromyelitis optica spectrum disorder**
Qian Yu (*Medical University of Vienna - Vienna, Austria*)
- 15:06-15:13 **PK-356 | Increase in Cytotoxic Eomes-Expressing Helper T cells Associated with Refractory Neuromyelitis Optica**
Eiichiro Amano (*National Institute of Neuroscience, National Center of Neurology and Psychiatry - Kodaira, Japan*)
- 15:13-15:20 **PK-349 | The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD**
Sara Samadzadeh (*University of Oxford - Oxford, UK*)
- 15:20-15:27 **PK-252 | Temporal change in the treatment of MS and NMOSD with novel DMD in Tohoku University over the past 5 years**
Kimihiro Kaneko (*Tohoku University Hospital – Sendai, Japan*)
- 15:27-15:34 **PK-131 | Neuropsychological impairment in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes**
Katherine Ko (*Monash University – Melbourne, Australia*)
- 15:34-15:41 **PK-364 | Human CASPR2 autoantibodies disrupt neuronal network excitability through binding to the CASPR2 shed ectodomain**
Debora Serrenho (*CNC – Centre for Neuroscience and Cell Biology - Coimbra, Portugal*)

15:45 – 16:05 COFFEE BREAK

16:05 – 17:20

Convention Hall

Symposium 9 | Microglia

Chairs: Veronique Miron (*Canada*) & Takahiro Masuda (*Japan*)

- 16:05-16:25 **Single-cell analysis reveals shared inflammatory glial states across CNS neurodegenerative diseases**
Brian Hafler (*Yale School of Medicine/the Broad Institute of Harvard/MIT – New Haven, CT/Boston, MA – USA*)
- 16:25-16:45 **Understanding the multifaceted characteristics of brain macrophages**
Takahiro Masuda (*Kyushu University – Fukuoka City, Japan*)
- 16:45-17:05 **Microglia prevent spontaneous and recurring CNS demyelination**
Veronique Miron (*Unity Health Toronto & The University of Toronto – Toronto, ON, Canada*)
- 17:05-17:20 **O491 | Complement factor C5a, and granulocyte and astrocyte markers in CSF associate with disability in myelin oligodendrocyte glycoprotein antibody-associated disease and neuromyelitis optica spectrum disorder, and differentiate in acute stages versus MS**
David Leppert (*University Hospital and University of Basel - Basel, Switzerland*)

International Conference Room - Novartis Hall

Symposium 10 | Regulatory Gene & Environmental Factors in MS (2) - Novel Research Strategy to reveal pathomechanisms of neuroimmunological diseases

Chairs: Anne-Katrin Pröbstel (*Germany*) & Sachiko Miyake (*Japan*)

- 16:05-16:25 **MS Causation and Progression-Environmental Factors**
Helmut Butzkueven (*Monash University – Melbourne, Australia*)
- 16:25-16:45 **Genetic contributions to risk and progression in multiple sclerosis**
Adil Harroud (*Montreal, QC, Canada*)
- 16:45-17:05 **The ancient origins of risk to the multiple sclerosis**
Lars Fugger (*University of Oxford – Oxford, UK*)
- 17:05-17:20 **O186 | The multiple sclerosis associated CD226 risk variant alters vitamin D-induced human type I regulatory T cell differentiation by impairing LFA-1 activation**
Anne Astier (*INSERM U1291 – Toulouse, France*)

Room 201 - Merck Hall

Symposium 11 | BBB & T cell Trafficking

Chairs: Britta Engelhardt (*Switzerland*) & Masato Yasui (*Japan*)

- 16:05-16:25 **Imaging the role of the brain barriers in CNS immune privilege**
Britta Engelhardt (*University of Bern – Bern, Switzerland*)
- 16:25-16:45 **The lung–Brain axis in CNS autoimmunity**
Alexander Flügel (*University Medical Center Göttingen, Georg-August University – Göttingen, Germany*)
- 16:45-17:05 **Brain endothelial cells are effectors of damage in MS**
Alexandre Prat (*CHUM, Université de Montréal – Montreal, QC, Canada*)
- 17:05-17:20 **O18 | Antigen-specific interactions between endothelial cells of the blood-brain barrier and CD8 T cells**
Carmen Gonzalez Fierro (*Toulouse Institute for infectious and inflammatory diseases (Infinity) - Toulouse, France*)

Room 301 - Mitsubishi Tanabe Hall

Symposium 12 | Investigator-initiated Clinical Trials in Neuroimmunology

Chairs: Sonoko Misawa (*Japan*) & Fumitaka Shimizu (*Japan*)

- 16:05-16:25 **Development of Thalidomide for POEMS Syndrome**
Sonoko Misawa (*Chiba University Graduate School of Medicine – Chiba, Japan*)

- 16:25-16:45 **Potential novel therapeutic agent with unique mechanism of action for multiple sclerosis: OCH**
Tomoko Okamoto (*National Center of Neurology and Psychiatry – Kodaira, Japan*)
- 16:45-17:05 **An exploratory, placebo-controlled, double-blind, phase II study to evaluate the efficacy and safety of rituximab in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)**
Wakiro Sato (*National Center of Neurology and Psychiatry (NCNP) – Kodaira, Japan*)
- 17:05-17:20 **OCH, a new immunomodulatory drug for MS treatment: insights from translational and mechanistic studies**
Ben Raveney (*National Institute of Neuroscience, NCNP – Kodaira, Japan*)

17:20 – 17:50

Convention Hall

Plenary Lecture 3

Chair: Roland Liblau (*France*)

- 17:20-17:50 **Th17 cells in the induction of Neuroinflammation**
Vijay Kuchroo (*Harvard Medical School, Brigham & Women's Hospital – Boston, MA, USA*)

17:50 – 19:15

Room 101B - 105

Poster Session 1

19:45 **SOCIAL DINNER** at Hotel New Otani Makuhari

DAY 3 | October 7

08:15 – 09:00

Convention Hall

Morning Lecture 2

Chair: Michal Schwartz (*Israel*)

- 08:15-09:00 **New blind spots in CNS immune privilege**
Jonathan Kipnis (*WashU Medicine in St. Louis – St. Louis, MO, USA*)

International Conference Room - Novartis Hall

Morning Lecture for Clinical Topic 2 | Introductory Lecture on MG

Chair: Takayuki Kondo (*Japan*)

- 08:15-09:00 **MG Today: Shifting Treatment Paradigms and Clinical Challenges**
Mitsuru Watanabe (*Kyushu University Hospital – Fukuoka, Japan*)

09:00 – 09:30

Convention Hall

Plenary Lecture 4

Chair: Olga Rojas (*Canada*)

- 09:00-09:30 **Neurovascular interactions: From mechanisms to clinical trials**
Katerina Akassoglou (*University of California San Francisco – San Francisco, CA, USA*)

09:30 – 11:10

Convention Hall

Symposium 13 | Potential New Therapy

Chairs: Amit Bar-Or (USA) & Sean Pittock (USA)

- 09:30-09:50 **Nasal immunotherapy in neurologic diseases**
Howard Weiner (Boston, MA, USA)
- 09:50-10:10 **CAR T-cell therapy in diseases of the nervous system**
Ralf Gold (Bochum, Germany)
- 10:10-10:30 **Sustaining microglial reparative function enhances stroke recovery**
Takashi Shichita (Institute of Science Tokyo – Tokyo, Japan)
- 10:30-10:50 **Immunotherapy to combat Alzheimer's disease**
Michal Schwartz (The Weizmann Scientific Institute - Rehovot, Israel)
- 10:50-11:10 **O474 | Fibrin Targeted Immunotherapy Protects Against Inflammation and Neuropathology**
Hisao Miyajima (Gladstone and UCSF - San Francisco, CA, USA)

International Conference Room - Novartis Hall

Symposium 14 | Glial Cells: Biology & Disease

Chair: Oleg Butovsky (USA) & Kimitoshi Kimura (Japan)

- 09:30-09:50 **Microglia and chronic pain**
Makoto Tsuda (Kyushu University – Fukuoka City, Japan)
- 09:50-10:10 **APOE4-TGF β Signaling Drives Immune Checkpoint Pathways that Restrain Microglial Response in Alzheimer's Disease**
Oleg Butovsky (Brigham and Women's Hospital, Harvard Medical School – Boston, MA, USA)
- 10:10-10:30 **Precise Microglial Regulation: Toward Novel Therapeutic Strategies for CNS Diseases**
Kimitoshi Kimura (Kyoto University Graduate School of Medicine – Kyoto, Japan)
- 10:30-10:50 **Microglia-neuron crosstalk through β -hexosaminidase-GM2-MGL2 maintains brain homeostasis**
Maximilian Frosch (University of Freiburg – Freiburg, Germany)
- 10:50-11:10 **O189 | Microglia-Driven Brain Repair and Cognitive Recovery**
Agnieszka Włodarczyk (University of Southern Denmark - Odense, Denmark)

Room 201 - Merck Hall

Symposium 15 | Neuropathology of MS/NMO: updated

Chairs: Izumi Kawachi (Japan) & Tatsuro Misu (Japan)

- 09:30-09:50 **Essential Differences in Pathology between MS and MOGAD**
Hans Lassman (Medical University of Vienna – Vienna, Austria)
- 09:50-10:10 **Neuropathology of NMOSD and MOGAD**
Tasuro Misu (Tohoku University Hospital – Sendai, Japan)
- 10:10-10:30 **Stage-dependent immune dynamics orchestrate CNS pathology in NMOSD and MS**
Izumi Kawachi (Niigata University School of Medicine – Niigata, Japan)
- 10:30-10:50 **O244 | Spatial multiome profiling reveals molecular cell type changes in early multiple sclerosis lesions**
Patricia Sekol (Heidelberg University - Mannheim, Germany)
- 10:50-11:10 **O75 | AQP4-specific T cells determine lesion localization in the CNS in a model of NMOSD**
Ali Maisam Afzali (Technical University of Munich (TUM) Klinikum, School of Medicine and Health - Munich, Germany)

Room 301 - Mitsubishi Tanabe Hall

Symposium 16 | Gut-brain Axis & Microbiome

Chairs: Jen Gommerman (*Canada*) & Anneli Peters (*Germany*)

- 09:30-09:50 **Uncovering the novel function of interleukin-17**
Jun Huh (*Boston, MA, USA*)
- 09:50-10:10 **How the microbiome shapes immune regulatory mechanisms**
Ari Waisman (*Mainz, Germany*)
- 10:10-10:30 **Fasting-Refeeding Paradigms Reshape Gut-Brain Interactions in CNS Inflammation**
Claudia Cantoni (*Barrow Neurological Institute – Phoenix, AZ, USA*)
- 10:30-10:50 **O340 | Gut CD8+ gamma-delta T cells mediate neuropathology in Parkinson's disease**
Rhonda McFleder (*Universitätsklinikum Würzburg - Würzburg, Germany*)
- 10:50-11:10 **O357 | Lachnospiraceae from the ileum of Multiple Sclerosis twins trigger MS-like disease in germfree transgenic mice**
Anneli Peters (*LMU Hospital - Munich, Germany*)

11:10 - 11:30 COFFEE BREAK

11:30 – 12:30

International Conference Room - Novartis Hall

Round Table | Industry Discussions

12:30 – 13:30

Convention Hall

Lunch Seminar (LT-8) | Chugai Pharmaceuticals

Chair: Takashi Yamamura (*National Center of Neurology and Psychiatry – Tokyo, Japan*)

- 12:30-13:30 **IL-6 and semaphorins: neuro-immuno-metabolic linkage**
Atsushi Kumanogoh (*Osaka University – Osaka, Japan*)

International Conference Room - Novartis Hall

Lunch Seminar (LT-9) | Novartis

Chair: Tatsusada Okuno (*Hospital Professor, Department of Neurology, The University of Osaka Graduate School of Medicine – Osaka, Japan*)

Optimizing long term outcomes for people with MS through early diagnose and highly effective therapies

Wallace Brownlee (*Consultant Neurologist & Clinical Lead for MS at the National – Cleveland, OH, USA*)

Room 301 - Mitsubishi Tanabe Hall

Lunch Seminar (LT-11) | Biogen

Chair: Jin Nakahara (*Keio University – Tokyo, Japan*)

States of the art in treating patients with multiple sclerosis in Japan

Norio Chihara (*Division of Neurology, Kobe University Graduate School of Medicine – Hyogo, Japan*)

Room 302

Meet the Experts 3

Room 303

Meet the Experts 4

13:30 – 14:50

Convention Hall

Symposium 17 | Alzheimer's Disease: New Perspective

Chair: John Lukens (USA) & Francisco Quintana (USA)

- 13:30-13:50 **Peripheral myeloid cell regulation of cognitive decline in Alzheimer's disease and aging**
Hannah Ennerfelt (*Postdoctoral scholar, Stanford University – Stanford, CA, USA*)
- 13:50-14:10 **Role of Innate Immune Dysfunction in Alzheimer's Disease**
John R. Lukens (*University of Virginia, Center for Brain Immunology and Glia (BIG) – Charlottesville, VA, USA*)
- 14:10-14:30 **Amyloid- β aggregates are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease**
Kenjiro Ono (*Kanazawa University Graduate School of Medical Sciences – Kanazawa, Japan*)
- 14:30-14:50 **O91 | Chronic stress attenuates CNS myeloid cell function and neurotoxicity in Alzheimer's disease**
Yoel Shor (*The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center - Jerusalem, Israel*)

International Conference Room - Novartis Hall

Symposium 18 | Neuro-immune Crosstalk

Chairs: Thomas Korn (Germany) & Vijay Kuchroo (USA)

- 13:30-13:50 **TBD**
Hai Qi (*Beijing, China*)
- 13:50-14:10 **Neuroimmune crosstalk in the lungs: nociceptors and myeloid cells in viral infection**
Isaac Chiu (*Harvard Medical School – Boston, MA, USA*)
- 14:10-14:30 **Peripheral neuroimmune interactions and atopic dermatitis**
Nicolas Gaudenzio (*Infinity-Inserm / Genoskin – Toulouse, France*)
- 14:30-14:50 **O472 | Astrocyte-targeted Amphiregulin therapy promotes immune suppression and remyelination in multiple sclerosis mouse models**
Sadia Shaukat (*KU Leuven - Leuven, Belgium*)

Room 201 - Merck Hall

Symposium 19 | Destructive & Protective Immunity in Neurodegenerative Conditions

Chairs: Ana Anderson (USA) & Yusei Miyazaki (Japan)

- 13:30-13:50 **Alpha-Synuclein orchestrates Th17 responses as antigen and adjuvant in Parkinson's disease**
Sachiko Miyake (*Juntendo University Graduate School of Medicine – Tokyo, Japan*)
- 13:50-14:10 **The Role of CD8⁺ T Cells in Neurodegeneration**
Norio Chihara (*Kobe University Graduate School of Medicine – Kobe, Japan*)
- 14:10-14:30 **Multilayered mechanism of neuronal cell death in neurodegenerative diseases**
Shinji Oki (*National Center of Neurology and Psychiatry (NCNP) – Kodaira, Japan*)
- 14:30-14:50 **O273 | Intersection of IL-23 and steroid signaling in the regulation of Th17 cell state**
Ana Anderson (*Brigham and Women's Hospital – Boston, MA, USA*)

Room 301 - Mitsubishi Tanabe Hall

Symposium 20 | MG/CIDP

Chair: Yuko Shimizu (Japan) & Fumitaka Shimizu (Japan)

- 13:30-13:50 **Blood-nerve barrier breakdown in chronic inflammatory demyelinating polyneuropathy**
Fumitaka Shimizu (*Yamaguchi University Graduate School of Medicine – Ube, Japan*)

- 13:50-14:10 **O316 | Parasite-mediated disruption of antigen presentation facilitates immune evasion and maintenance of the brain-persisting *Toxoplasma gondii* parasite**
Nicolas Blanchard (*Université de Toulouse - Toulouse, France*)
- 14:10-14:30 **O327 | Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis**
Veronica Morcone (*Università Cattolica del Sacro Cuore – Rome, Italy*)
- 14:10-14:30 **Next-Generation Treatment of Myasthenia Gravis with Fc Fusion Proteins**
Akiyuki Uzawa (*Chiba University- Chiba, Japan*)

14:50 – 15:20

Convention Hall

ISNI Keynote Lecture | The Immunology Lecture

Chair: Ichiro Nakashima (*Japan*)

- 14:50-15:20 **B cell directed therapies in neuroinflammation – Exploring mechanisms of action**
Jen Gommerman (*University of Toronto – Toronto, ON, Canada*)

15:20 - 15:40 COFFEE BREAK

15:40 – 16:40

Convention Hall

ISNI Mid-Career Award

Chairs:

Introduction

Veronique Miron - Fundamental
Anne-Katrin Pröbstel - Clinical
Qiang Liu - Clinical

16:40 – 18:20

International Conference Room - Novartis Hall

Tech Symposium | Novel Research Strategy to reveal pathomechanisms of neuroimmunological diseases

Chairs: Carmen Scheibenbogen (*Germany*) & Adil Harroud (*Canada*)

- 16:40-17:00 **New Methods for Transcriptome Analysis**
Yutaka Suzuki (*The University of Tokyo – Tokyo, Japan*)
- 17:00-17:20 **Bridging single cell analysis with clinical insights for autoimmune rheumatic diseases**
Masayuki Nishide (*The University of Osaka – Osaka, Japan*)
- 17:20-17:40 **Deciphering neuroinflammatory disease through multi-omics approach**
Sho Yamasaki (*Osaka University – Osaka, Japan*)
- 17:40-18:00 **New Methods for microbiome analysis**
Wataru Suda (*Kyushu University – Fukuoka City, Japan*)
- 18:00-18:20 **Assessing Mitophagy and the Downstream Effects in Neuroinflammation**
Atsushi Kadowaki (*Osaka University Graduate School of Medicine – Osaka, Japan*)

16:40 – 17:40

Room 201 - Merck Hall

Sponsored Symposium (LT-10) | Alexion - Complement Component 5 Inhibitor Therapies (C5ITs) in Neuromyelitis Optica Spectrum Disorder (NMOSD): Clinical Insights and Real-World Evidence

Chair: Takashi Yamamura (*National Center of Neurology and Psychiatry – Tokyo, Japan*)

Unmet Needs and the Evolution of the Treatment Paradigm in AQP4-Ab+ NMOSD

Sean Pittock (*Mayo Clinic Rochester, United States*)

Real-World Insights on the Safety and Effectiveness of C5ITs in AQP4-Ab+ NMOSD in Japan and the Global NMO SPOTLIGHT Registry

Noriko Isobe (*Kyushu University Fukuoka, Japan*)

18:20 – 19:40

Room 101B – 105

Poster Session 2

18:40 – 19:40

Convention Hall

ISNI General Assembly

DAY 4 | October 8

08:15 – 09:00

Convention Hall

Morning Lecture 3

Chair: Kazuhiko Yamamoto (*Japan*)

08:15-09:00 **The Gut-Brain Axis in Homeostasis Regulating Behavior**
David Hafler (*Yale School of Medicine – New Haven, CT, USA*)

International Conference Room - Novartis Hall

Morning Lecture on Clinical Topic 3 | Introductory Lecture on Alzheimer

Chair:

08:15-09:00 **Passive and active immunization therapy for Alzheimer's disease targeting amyloid beta present and future**
Takeshi Tabira (*Juntendo University - Tokyo, Japan*)

09:00 – 09:30

Convention Hall

ISNI Keynote Lecture | The Dale McFarlin Lecture

Chair: Fabienne Brilot (*Australia*)

09:00-09:30 **Liquid biopsies in MS and related diseases**
Anne Cross (*Washington University School of Medicine in St Louis – St. Louis, MO, USA*)

09:30 – 09:50 COFFEE BREAK

09:50 – 11:30

Convention Hall

Symposium 21 | Infectious Agents, Molecular Mimicry & Neuroimmunological Disorders

Chairs: Carmen Scheibenbogen (Germany) & Tobias Lanz (USA)

- 09:50-10:10 **EBV and MS: Molecular mimicry and beyond**
Tobias Lanz (Stanford School of Medicine – Stanford, CA, USA)
- 10:10-10:30 **CNS-resident memory T cells in neuroinflammatory diseases**
Roland Liblau (Toulouse University Hospital – Toulouse, France)
- 10:30-10:50 **ME/CFS and Long Covid: the role of autoimmunity**
Carmen Scheibenbogen (Charité – Universitätsmedizin Berlin – Berlin, Germany)
- 10:50-11:10 **Molecular mimicry as a key mechanism to trigger and sustain multiple sclerosis**
Roland Martin (University of Zurich – Zürich, Switzerland / Karolinska Institutet – Stockholm, Sweden / Cellerys AG – Schlieren, Switzerland)
- 11:10-11:30 **O345 | Cytomegalovirus drives the development of natalizumab-resistant cytotoxic CD4+ T cells in patients with multiple sclerosis**
Niels Hellings (Biomedical Research Institute (BIOMED) & University MS Center (UMSC), Hasselt University - Diepenbeek, Belgium)

International Conference Room - Novartis Hall

Symposium 22 | ISNI Young Session - Sponsored by Elsevier/Journal of Neuroimmunology (JNI)

Chairs: Olga Rojas (Canada) & Veit Rothhammer (Germany)

- 09:50-10:10 **O46 | The dura mater harbours heterogeneous fibroblasts and undergoes remodelling of fibroblasts in chronic multiple sclerosis**
Anna-Lena Börsch (University Hospital Münster – Münster, Germany)
- 10:10-10:30 **O88 | Investigation of Blood–Brain Barrier Dysfunction in Multiple Sclerosis According to Clinical Subtype and Genetic Background**
Kinya Matsuo (Yamaguchi University Graduate School of Medicine - Yamaguchi, Japan)
- 10:30-10:50 **O143 | IL-9/IL-9R signalling modulates synaptic genes in spinal cord neurons with implications for amyotrophic lateral sclerosis**
Costanza Stacchiotti (IRCSS Fondazione Santa Lucia - Rome, Italy)
- 10:50-11:10 **O169 | Characterization of HLA-restricted GAD65-specific CD8+ T cell responses in patients with GAD65 antibody-associated disorders**
Pei Shang (Mayo Clinic – Rochester, MN, USA)
- 11:10-11:30 **O342 | Monocyte desensitization in myalgic encephalomyelitis/chronic fatigue syndrome: A potential driver of energy depletion and neuroimmune dysregulation**
Manu Mallahalli (National Institute of Neuroscience, National centre of Neurology and Psychiatry - Kodaïra, Japan)

Room 201 - Merck Hall

Symposium 23 | Human Immunology & Neuroimmunology

Chair: David Leppert (Switzerland) & Ben Raveney (Japan)

- 09:50-10:10 **Autoreactive T cell immunity in inflammatory peripheral neuropathies**
Daniela Latorre (IRCSS San Raffaele Hospital – Milan, Italy)
- 10:10-10:30 **O151 | Perturbances in circulating B and CD4+ T cells is a discriminating feature of multiple sclerosis**
Kirsten Kuiper (Erasmus MC, MS Center ErasMS - Rotterdam, The Netherlands)
- 10:30-10:50 **O69 | Fibronectin: A Potential Therapeutic Target to Restore Blood–Brain Barrier Integrity in Multiple Sclerosis**
Hideaki Nishihara (Yamaguchi University – Yamaguchi, Japan)

- 10:50-11:10 **O102 | Single-cell analysis of skin, blood, and cerebrospinal fluid reveals an impaired systemic immune response to ultraviolet B radiation in multiple sclerosis**
Simon Falk (*University of Münster - Münster, Germany*)
- 11:10-11:30 **TBD**
Yukinori Okada (*Riken Center for Integrative Medical Sciences - Yokohama, Japan*)

Room 301 - Mitsubishi Tanabe Hall

Symposium 24 | Hot Topics in Neuroimmunology Research

Chair: Maja Jagodic (*Sweden*) & Luc Vallières (*Canada*)

- 09:50-10:10 **O319 | Neuronal Vulnerability to Iron Is Linked to Impaired Antioxidant Activation**
Dorsa Moezzi (*Hotchkiss Brain Institute, University of Calgary – Calgary, AB, Canada*)
- 10:10-10:30 **O208 | Preclinical evaluation of an optimized IL-2-based Treg-targeting immunomodulatory treatment in a mouse model of Tauopathy**
Inès El Haddad (*Sorbonne University, INSERM, Saint-Antoine Hospital - Paris, France*)
- 10:30-10:50 **O71 | skull periosteum — an immune-relevant tissue**
Sheng-Hsiang Shen (*University Hospital Münster - Münster, Germany*)
- 10:50-11:10 **O92 | Astrocytic Cystatin C effects on Experimental Autoimmune Encephalomyelitis**
Shalina Ousman (*University of Calgary, Hotchkiss Brain Institute – Calgary, AB, Canada*)
- 11:10-11:30 **O263 | Cellular and soluble determinants for successful tolerogenic mRNA immunotherapy**
Siri Tahtinen (*Genentech - South San Francisco, CA, USA*)

11:30 – 12:00

Convention Hall

Henry McFarland Memorial Lecture

Chair: Amit Bar-Or (*USA*)


Translational neuroimmunology as Henry McFarland's legacy



Roland Martin (*University of Zurich – Zürich, Switzerland/Karolinska Institutet – Stockholm, Sweden/Cellerys AG – Schlieren, Switzerland*)

12:00 – 12:30

Convention Hall

Closing Ceremony & Awards





Sponsors

Gold Plus



Gold



 A member of the Roche group

Silver



Contributors

